Fundraising Fox
Abk Biomedical Inc
Halifax, CA · Founded 2012 · Nova Scotia, Canada corporation · 41 employees on LinkedIn · 4 known investors
Find your way into Abk Biomedical Inc
434 people in our graph can introduce you to the Abk Biomedical Inc team.
Sign up to see every warm intro you have to Abk Biomedical Inc
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Abk Biomedical Inc team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ABK Biomedical is a clinical-stage medical device company that develops x-ray visible glass microspheres for Y-90 radioembolization and embolic treatment of cancers such as liver cancer. Spun out of Dalhousie University, it serves interventional oncology and radiology applications.
Founders & leadership
Abk Biomedical Inc was founded in 2012 by Robert Abraham, Daniel Boyd, and Sharon Kehoe.
RA
Robert AbrahamCo-founder (Interventional Radiologist, MD)Robert Abraham is an interventional radiologist and physician with board certification (FRCPC) and fellowship credentials in interventional radiology (FSIR, FCIRSE). He co-founded ABK Biomedical, a clinical-stage medical device company developing x-ray visible microspheres for radioembolization and cancer treatment, spun out of Dalhousie University.
DB
Daniel BoydCo-founder (Material Scientist)Daniel Boyd is a material scientist and co-founder of ABK Biomedical, a clinical-stage medical device company developing x-ray visible glass microspheres for Y-90 radioembolization in cancer treatment. With nearly two decades of experience in academic research and product development, he has founded multiple medical device companies and holds numerous patents.
SK
Sharon KehoeCo-founder (Material Scientist)Sharon Kehoe is a material scientist and co-founder of ABK Biomedical, a clinical-stage medical device company developing x-ray visible glass microspheres for radioembolization and cancer treatment. Her background spans biomaterial formulation, tissue engineering, and biological evaluation of medical materials.
AH
Anthony HeadleySVP, Manufacturing, R&D, and EngineeringAnthony Headley has spent over two decades as a medical device executive, holding director and senior leadership roles at companies including Boston Scientific, Symbiosis, Enpath Medical, Kimberly-Clark Healthcare, and Hollister Incorporated, with expertise spanning product development, manufacturing, operations, and R&D across gastrointestinal, respiratory, vascular, and neurostimulation devices.
GD
Gary DonofrioChief Business OfficerGary Donofrio is an executive officer at ABK Biomedical, a clinical-stage medical device company developing x-ray visible glass microspheres for radioembolization treatment. He has background in sales management, product management, and marketing across multiple regions and product lines.
MM
Michael ManganoPresident and CEOMichael Mangano is an executive officer and director at ABK Biomedical, a clinical-stage medical device company spun out of Dalhousie University. He brings over thirty years of experience in the medical device industry across sales, marketing, product development, strategic planning, and business development.
DD
David DobrowskyExecutive
LB
Lucy BataneantExecutive
MT
Mike TysonCFOMike Tyson is Executive Officer at ABK Biomedical, a clinical-stage medical device company developing glass microspheres for Y-90 radioembolization. He previously served as VP Finance at AqueSys, which was acquired by Allergan, and has held finance and operations roles across life science and medical device companies.
DD
David DobrowskiVice President Clinical Development & Regulatory AffairsExecutive with experience in pharmaceutical and medical device sectors across multiple therapeutic areas, including roles in product development and commercialization, and team building.
JM
James McLarenNamed on SEC filing
Investors · 4
Eight Roads Ventureslisted by Eight Roads VenturesMumbai · $5M – $30M
How we know: Eight Roads Ventures's portfolio page · Not right? Tell us
F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M
How we know: F-Prime Capital's portfolio page · a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$80.7M disclosed across 4 rounds · 2019–2025
▶$2.6MraisedNov 2025 · 6 investors · OtherRule 506(b)
▶$2.6MraisedNov 2025 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Lucy BataneantExecutive Officer
- Aravind ArepallyExecutive Officer
- David DobrowskyExecutive Officer
- Joseph SilettoDirector
- James McLarenDirector
- Marc GregoireExecutive Officer
- Aaron BerezDirector
- Keten PatelDirector
- Anthony HeadleyExecutive Officer
- Carissa Bellardine BlackDirector
- Mike TysonExecutive Officer
- James EadieDirector
- Gary DonofrioExecutive Officer
- Michael ManganoExecutive Officer, Director
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- First sale
- Oct 2025
- Incorporated
- Corporation, Nova Scotia, Canada
- Federal exemptions
- 06b
▶$26.1MraisedMay 2025 · 24 investors · OtherRule 506(b)
▶$26.1MraisedMay 2025 · 24 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Anthony HeadleyExecutive Officer
- Gary DonofrioExecutive Officer
- Michael ManganoExecutive Officer, Director
- David DobrowskyExecutive Officer
- Keten PatelDirector
- Lucy BataneantExecutive Officer
- Joseph SilettoDirector
- Marc GregoireExecutive Officer
- Carissa Bellardine BlackDirector
- Aaron BerezDirector
- James EadieDirector
- Mike TysonExecutive Officer
- James McLarenDirector
- Aravind ArepallyExecutive Officer
- Offering amount
- $26.1M
- Amount sold
- $26.1M
- First sale
- Apr 2025
- Incorporated
- Corporation, Nova Scotia, Canada
- Federal exemptions
- 06b
▶$28.5MraisedDec 2022 · 23 investors · OtherRule 506(b)
▶$28.5MraisedDec 2022 · 23 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Anthony HeadleyExecutive Officer
- Ketan PatelDirector
- Marc GregoireExecutive Officer
- Aravind ArepallyExecutive Officer
- Michael ManganoExecutive Officer, Director
- David DobrowskiExecutive Officer
- Aaron BerezDirector
- James McLarenDirector
- Mike TysonExecutive Officer
- Gary DonofrioExecutive Officer
- Carissa BlackDirector
- Offering amount
- $28.5M
- Amount sold
- $28.5M
- First sale
- Dec 2022
- Incorporated
- Corporation, Nova Scotia, Canada
- Federal exemptions
- 06b
▶$23.5MraisedApr 2019 · 10 investors · BiotechnologyRule 506(b)
▶$23.5MraisedApr 2019 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James McLarenDirector
- Michael TysonExecutive Officer
- David DobrowskiExecutive Officer
- Robert OrrDirector
- Aaron BerezDirector
- Bob AbrahamExecutive Officer, Director
- Marc GregoireExecutive Officer
- Michael ManganoExecutive Officer, Director
- Gary DonofrioExecutive Officer
- Offering amount
- $23.5M
- Amount sold
- $23.5M
- First sale
- Apr 2019
- Incorporated
- Corporation, Nova Scotia, Canada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
ToperaAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
Companies working in the same space as Abk Biomedical Inc.
Frequently asked questions
- What does Abk Biomedical Inc do?
- ABK Biomedical is a clinical-stage medical device company that develops x-ray visible glass microspheres for Y-90 radioembolization and embolic treatment of cancers such as liver cancer. Spun out of Dalhousie University, it serves interventional oncology and radiology applications.
- Who founded Abk Biomedical Inc?
- Abk Biomedical Inc was founded by Robert Abraham, Daniel Boyd, Sharon Kehoe in 2012.
- Who are Abk Biomedical Inc's investors?
- Abk Biomedical Inc's investors include Eight Roads Ventures, F-Prime Capital, First Angel Network Association (FAN), Vivo Capital.
- How much funding has Abk Biomedical Inc raised?
- Abk Biomedical Inc has disclosed $80.7M raised across 4 rounds.
- Where is Abk Biomedical Inc headquartered?
- Abk Biomedical Inc is headquartered in Halifax, CA.